Login to Your Account



Other News To Note


Friday, February 4, 2011
Digna Biotech SL, of Madrid, Spain, and the Centro de Investigacion Medica Aplicada de la Universidad de Navarra said the European Union finalized a €3.3 million (US$4.5 million) grant to AIPGENE consortium and, as members of the consortium, Digna and CIMA will receive €500,000 and €800,000, respectively, for the clinical development of a gene therapy product for acute intermittent porphyria. As part of the grant, they will complete a Phase I/II study, with patient enrollment slated to start in early 2012.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription